Business Wire

Knopp Biosciences NIH-funded Pain Program Advances to Third Year of HEAL Award to Discover Non-Opioid Treatments for Chronic Pain

Share

Knopp Biosciences LLC today announced that it was awarded a third year of research funding by the National Institutes of Health (NIH) to advance the development of its novel non-opioid therapies for the treatment of chronic pain. The project is funded by the NIH Helping to End Addiction Long-term Initiative (NIH HEAL Initiative), which aims to improve treatments for chronic pain, curb the rates of opioid use disorder and overdose, and achieve long-term recovery from opioid addiction.

Knopp has developed a discovery platform of proprietary molecules directed to a non-opioid biological target linked to chronic pain caused by damage to nerves. The drug target is a cellular membrane potassium channel called Kv7.2/7.3, which regulates the flow of ions required to modulate the excitability of cells. Growing scientific evidence suggests that selectively activating key Kv7 channel subtypes can control nerve-cell hyperexcitability associated with transmission of chronic pain.

“Receiving this next phase of HEAL funding, based on promising results in preclinical models of chronic and neuropathic pain, positions Knopp to advance our lead drug candidate into IND-enabling studies,” said Michael Bozik, M.D., Chief Executive Officer of Knopp. “We are excited to make continuing progress in this important initiative addressing an immense and persistent public-health challenge.”

Year three funding of $2.2 million is part of as much as $8 million in support contingent upon the attainment of milestones over five years. Knopp’s HEAL award was highly competitive and one of 375 grants made across 41 states in fiscal year 2019 to apply scientific solutions to help reverse the national opioid crisis.

Knopp’s Kv7 research is supported in part under Award Number U44NS093160 and Award Number U44NS115732 of the National Institute of Neurological Disorders and Stroke of the NIH. The content of this announcement is solely the responsibility of Knopp and does not necessarily represent the views of the NIH.

ABOUT KNOPP BIOSCIENCES LLC

Knopp Biosciences is a privately held drug discovery and development company focused on delivering breakthrough treatments for immunological and neurological diseases of high unmet need. Knopp’s clinical-stage oral small molecule, dexpramipexole, is in Phase 2 clinical trials in moderate-to-severe eosinophilic asthma. Knopp’s preclinical Kv7 platform is directed to small molecule treatments for developmental and epileptic encephalopathies, other rare epilepsies, neuropathic pain, and smooth muscle disorders. Please visit www.knoppbio.com.

ABOUT THE NIH HEAL INITIATIVE

The Helping to End Addiction Long-term℠ Initiative, or NIH HEAL Initiative℠, is an aggressive, trans-NIH effort to speed scientific solutions to stem the national opioid public health crisis. Launched in April 2018, the initiative is focused on improving prevention and treatment strategies for opioid misuse and addiction, and enhancing pain management. For more information, visit: https://heal.nih.gov.

This press release contains “forward-looking statements,” including statements relating to planned regulatory filings and clinical development programs. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including the uncertainties inherent in clinical trials and product development programs, the availability of funding to support continued research and studies, the availability or potential availability of alternative therapies or treatments, the availability of patent protection for the discoveries and strategic alliances, as well as additional factors that may cause Knopp’s actual results to differ from our expectations. There can be no assurance that any investigational drug product will be successfully developed or manufactured or that final results of clinical studies will be supportive of regulatory approvals required to market a product. Knopp undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

Knopp’s pipeline consists of investigational drug products that have not been approved by the U.S. Food and Drug Administration. These investigational drug products are still undergoing pre-clinical or clinical study to verify their safety and effectiveness.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media inquiries:
Tom Petzinger
tom@knoppbio.com
+1-412-488-1776

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Wordley Partnership: New Partner Appointments Bolster Insurance, Commercial Litigation, International Arbitration and Corporate Practice7.12.2021 22:49:00 EET | Press release

International law firm Wordley Partnership has appointed two new partners, Costas Frangeskides and Simon Schindler. The appointments boost Wordley Partnership’s Insurance sector and Commercial groups. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211207006028/en/ Costas Frangeskides (Photo: Business Wire) Brief biographies are enclosed below: Costas is based in London and joins from leading international practice Holman Fenwick Willan (HFW) where he had been a partner since 2002 and is highly experienced in insurance and reinsurance disputes, commercial law, and international arbitration. He has a proven track record and has handled many high-profile commercial and insurance disputes. Commenting on the appointments, managing partner Paul Wordley of Wordley Partnership said: "We are delighted to announce Costas and Simon joining our team. This demonstrates our continuing commitment and expertise in the insurance markets, and

New Data Reveals Social Presence and Engagement Key to Streaming Growth7.12.2021 21:42:00 EET | Press release

Roughly 80% of social engagement for streaming platforms comes from Instagram, with TikTok close behind thanks to accounts like Netflix growing by more than a million followers each month in 2021. This is according to the Social Guide for Streaming report from Conviva, the continuous measurement platform for streaming media, which examined social engagement for more than 87 global streaming platforms and 695 streaming TV shows from January 1, 2021 to October 21, 2021. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211207005982/en/ Conviva’s State of Streaming: Social Guide for Streaming 2021 Publishers Report (Graphic: Business Wire) “A strong presence on social platforms like Facebook, Twitter and Instagram is critical for streaming publishers as it has been proven social is a key to content discovery,” said Keith Zubchevich, CEO, Conviva. “And, it’s not just about posting volume. The publishers that creatively and regularl

Andersen Global Strengthens European Platform with Addition of Collaborating Firm in Czech Republic7.12.2021 20:15:00 EET | Press release

Andersen Global enters into a Collaboration Agreement with Prague-based law firm rutland & partners, adding breadth to its platform in Europe. Rutland & partners, established in 2010 by Founding Partner Monika Rutland, focuses on corporate, real estate and M&A, providing legal services to businesses, foreign entities and private clients. Recognized by Chambers & Partners and The Legal 500, the firm offers full-service capabilities in litigation, employment, immigration, construction, pharmaceuticals and health care, banking, trust, and IT law. “Establishing long-lasting relationships and providing clients with quality, comprehensive solutions are integral aspects of our value-added service,” said Monika. “Our collaboration with Andersen Global further equips us to provide a seamless, integrated suite of services so clients can achieve their business objectives at the local and international levels.” Andersen Global Chairman and Andersen CEO Mark Vorsatz added, “rutland & partners compe

i2c Sets Industry Record with More Than 20 New Implementations Across 10 Markets in November7.12.2021 18:21:00 EET | Press release

i2c Inc., a leading provider of digital payment and banking technology, today announced it had deployed more than 20 new payment and digital banking programs for clients across 10 markets and four continents during the month of November alone. “The growth levels combined with the diversity of customers and programs we’re witnessing in our business today is a testament to our growth strategy and global team,” said Amir Wain, founder and CEO of i2c Inc. “We are thrilled to be the enabler of choice for visionaries in the payments and digital banking space as they work to accelerate financial innovation and expand access to millions of end users worldwide,” he said. i2c powers industry leaders in fintech, digital banking, cryptocurrency, as well as traditional financial institutions on a single, agile global platform. This fiscal half’s success includes new enterprise partners, as well as product and global program expansions for several U.S. and international programs, including: 1derful

Sunny Varkey Launches Tmrw, a New Learning Operating System (LearnOS) for Global Education to Bring a Quality Education Within Reach of Every Child7.12.2021 17:48:00 EET | Press release

Tmrw, a new and scalable Learning Operating System (LearnOS) for global education with a mission to help bring a quality education to every child, was launched this month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211207005768/en/ Sunny Varkey, Chairman and Founder of Tmrw (Photo: Business Wire) Its interoperable All-In-One Integrated Platform is built to be accessible and affordable for Government funded schools operating in both the developed and developing world settings. In particular, it seeks to reach all students irrespective of their background or their ability to pay. It is designed to cater to the needs of every curriculum, context and mode of learning, whether brick and mortar, virtual or blended. Tmrw’s vision over time is to underpin learning, teaching, and the operational needs of K12 education, higher education and life-long learning. Sunny Varkey, who also founded the Global Teacher Prize, has ensured th

Nexo Expands Institutional Access to Crypto in Collaboration with Fidelity Digital Assets7.12.2021 17:30:00 EET | Press release

Nexo , the leading regulated institution for digital assets, today announced its collaboration with Fidelity Digital AssetsSM, a leading institutional focused execution and custody services platform provider, to revolutionize institutional access to digital assets by together offering best-in-class custodial and lending services, including the launch of innovative institutional-focused products. Nexo, a pioneer of cryptocurrency-collateralized credit, and Fidelity Digital Assets as custodian and collateral agent, will develop a comprehensive product suite and compliant infrastructure for institutional investors seeking exposure to digital assets. As a first step, the collaboration with Fidelity Digital Assets will expand Nexo’s ability to service and enhance its growing portfolio of assets under management and will provide an additional custody layer to Nexo’s military-grade security infrastructure. This latest development gives institutional investors who currently custody their digit

Percona Platform Unifies Open Source Databases, Supports Private Database-as-a-Service Deployments7.12.2021 17:20:00 EET | Press release

Percona, a leader in open source database software and services, today announced Percona Platform to bring together database distributions, support expertise, services, management and automated insights into a single product. Building on the company’s expertise with databases including MySQL, PostgreSQL and MongoDB, the new Percona Platform will simplify how users monitor, manage and optimize their database instances across any infrastructure. In addition, Percona Platform will enable developers and database administrators to run their own private Database-as-a-Service (DBaaS) instances. This launch will preview the Percona Platform, allowing users to unify the entire database experience from packages and backup to monitoring and management, with general availability in early 2022. Percona brings together distributions of MySQL, PostgreSQL and MongoDB including a range of open source tools for data backup, availability and management. It also includes Percona Monitoring and Management

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom